☰

Sharareh Gholamin - Publications

Affiliations: 
2012-2017 Neurosurgery Stanford University School of Medicine, Palo Alto, CA, United States 
Website:
https://www.parkerici.org/person/sharareh-gholamin-phd/
Tree Info Grants Similar researchers PubMed Report error

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Gholamin S, Youssef OA, Rafat M, Esparza R, Kahn S, Shahin M, Giaccia AJ, Graves EE, Weissman I, Mitra S, Cheshier SH. Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma. Innate Immunity. 1753425919876690. PMID 31547758 DOI: 10.1177/1753425919876690  0.772
2019 Hutter G, Theruvath J, Graef CM, Zhang M, Schoen MK, Manz EM, Bennett ML, Olson A, Azad TD, Sinha R, Chan C, Assad Kahn S, Gholamin S, Wilson C, Grant G, et al. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 30602457 DOI: 10.1073/Pnas.1721434116  0.792
2018 Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, et al. Publisher Correction: Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications. 9: 4651. PMID 30389946 DOI: 10.1038/S41467-018-07182-1  0.736
2018 Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, et al. Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications. 9: 4121. PMID 30297829 DOI: 10.1038/S41467-018-06564-9  0.784
2018 Purzner T, Purzner J, Buckstaff T, Cozza G, Gholamin S, Rusert JM, Hartl TA, Sanders J, Conley N, Ge X, Langan M, Ramaswamy V, Ellis L, Litzenburger U, Bolin S, et al. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Science Signaling. 11. PMID 30206138 DOI: 10.1126/Scisignal.Aau5147  0.396
2017 Dos Santos Cavalcanti A, Meohas W, Ribeiro GO, de Sá Lopes AC, Gholamin S, Razavi M, Hanae Kasai Brunswick T, Avan A, Matheus Guimarães JA, Leite Duarte ME, Kahn SA. Patient-derived osteosarcoma cells are resistant to methotrexate. Plos One. 12: e0184891. PMID 28934267 DOI: 10.1371/Journal.Pone.0184891  0.733
2017 Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Science Translational Medicine. 9. PMID 28298418 DOI: 10.1126/Scitranslmed.Aaf2968  0.81
2017 Chang J, Mancuso MR, Maier C, Liang X, Yuki K, Yang L, Kwong JW, Wang J, Rao V, Vallon M, Kosinski C, Zhang JJ, Mah AT, Xu L, Li L, ... Gholamin S, et al. Gpr124 is essential for blood-brain barrier integrity in central nervous system disease. Nature Medicine. PMID 28288111 DOI: 10.1038/Nm.4309  0.69
2017 Gholamin S, Esparza R, Cheshier S, Mitra S. TRTH-32. COMBINATION IMMUNOTHERAPY TO ACTIVATE THE INNATE IMMUNE MICROENVIRONMENT AGAINST PEDIATRIC BRAIN TUMORS Neuro-Oncology. 19: iv58-iv59. DOI: 10.1093/Neuonc/Nox083.242  0.761
2017 Gholamin S, Kahn S, Esparza R, Weissman I, Mitra S, Cheshier S. IMMU-18. HUMANIZED ANTI-CD47 ANTIBODY COMBINED WITH AN AGONIST ANTI-CD40 ANTIBODY IS AN EFFECTIVE TREATMENT FOR DIPG XENOGRAFTS WITH CRANIOSPINAL DISSEMINATION Neuro-Oncology. 19: iv31-iv31. DOI: 10.1093/Neuonc/Nox083.128  0.789
2017 Hutter G, Theruvath JL, Kahn SA, Graef CM, Schoen MK, Gholamin S, Manz EM, Weissman IL, Mitra SS, Cheshier SH. OS01.4 Induction of differential macrophage and microglial glioblastoma phagocytosis by anti CD47 treatment - implication of tumor subtypes Neuro-Oncology. 19: iii1-iii2. DOI: 10.1093/Neuonc/Nox036.003  0.8
2016 Assad Kahn S, Costa SL, Gholamin S, Nitta RT, Dubois LG, Fève M, Zeniou M, Coelho PL, El-Habr E, Cadusseau J, Varlet P, Mitra SS, Devaux B, Kilhoffer MC, Cheshier SH, et al. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway. Embo Molecular Medicine. 8: 511-526. PMID 27138566 DOI: 10.15252/Emmm.201505421  0.751
2016 Zhang M, Hutter G, Kahn SA, Azad TD, Gholamin S, Xu CY, Liu J, Achrol AS, Richard C, Sommerkamp P, Schoen MK, McCracken MN, Majeti R, Weissman I, Mitra SS, et al. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo. Plos One. 11: e0153550. PMID 27092773 DOI: 10.1371/Journal.Pone.0153550  0.763
2016 Razavi SM, Lee KE, Jin BE, Aujla PS, Gholamin S, Li G. Immune Evasion Strategies of Glioblastoma. Frontiers in Surgery. 3: 11. PMID 26973839 DOI: 10.3389/Fsurg.2016.00011  0.397
2016 Kahn SA, Wang X, Nitta R, Gholamin S, Ramaswamy V, Azad T, Sahoo D, Esparza R, Chu P, Fisher P, Vogel H, Li G, Cho Y, Taylor M, Mitra S, et al. MB-16NOTCH1 PROMOTES GROUP 3 MEDULLOBLASTOMA METASTASIS, INITIATION AND SELF-RENEWAL Neuro-Oncology. 18: iii100.1-iii100. DOI: 10.1093/Neuonc/Now076.14  0.754
2016 Mitra S, Gholamin S, Feroze A, Weissman I, Cheshier S. HG-98IDENTIFICATION OF THE PRE-MALIGNANT CELL OF ORIGIN IN PEDIATRIC GLIOBLASTOMA MULTIFORME Neuro-Oncology. 18: iii71.2-iii71. DOI: 10.1093/Neuonc/Now073.94  0.784
2015 Mitra SS, Feroze AH, Gholamin S, Richard C, Esparza R, Zhang M, Azad TD, Alrfaei B, Kahn SA, Hutter G, Guzman R, Creasey GH, Plant GW, Weissman IL, Edwards MS, et al. Neural Placode Tissue Derived From Myelomeningocele Repair Serves as a Viable Source of Oligodendrocyte Progenitor Cells. Neurosurgery. PMID 26225855 DOI: 10.1227/Neu.0000000000000918  0.754
2015 Bui TT, Nitta RT, Kahn SA, Razavi SM, Agarwal M, Aujla P, Gholamin S, Recht L, Li G. γ-Glutamyl transferase 7 is a novel regulator of glioblastoma growth. Bmc Cancer. 15: 225. PMID 25884624 DOI: 10.1186/S12885-015-1232-Y  0.711
2015 Nitta RT, Gholamin S, Feroze AH, Agarwal M, Cheshier SH, Mitra SS, Li G. Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway. Oncogene. 34: 3688-99. PMID 25241897 DOI: 10.1038/Onc.2014.299  0.797
2015 Mitra SS, Gholamin S, Sinha R, Morganti RM, Weissman I, Cheshier SH. Abstract A11: Identification of the premalignant cell of origin in human glioblastoma multiforme Brain. 75. DOI: 10.1158/1538-7445.Brain15-A11  0.821
2015 Gholamin S, Mitra S, Esparza R, Liu J, Feroze A, Cho YJ, Zhang M, Vogel H, Edwards M, Weissman I, Cheshier S. IMPS-26HARNESSING THE MYELOID CHECKPOINT CD47-SIRPa AXIS AGAINST ADULT AND PEDIATRIC MALIGNANT BRAIN TUMORS: A NOVEL IMMUNOTHERAPEUTIC MODALITY Neuro-Oncology. 17: v118.4-v118. DOI: 10.1093/Neuonc/Nov217.25  0.825
2015 Kahn S, Nitta R, Wang K, Gholamin S, Azad T, Zhang M, Cho Y, Taylor M, Mitra S, Weissman I, Cheshier S. MB-01 * NOTCH1 PROMOTES MYC MEDULLOBLASTOMA METASTASIS, INITIATION AND MAINTENANCE Neuro-Oncology. 17: iii19-iii20. DOI: 10.1093/Neuonc/Nov061.77  0.813
2015 Gholamin S, Kahn SA, Esparza R, Hutter G, Feroze A, Weissman IL, Mitra SS, Cheshier SH. PM-08 * A HUMANIZED CO-TRANSPLANT XENOGRAFT MOUSE MODEL, TO STUDY TOXICITY OF DRUGS TARGETED AGAINST PEDIATRIC BRAIN TUMORS Neuro-Oncology. 17: iii32-iii32. DOI: 10.1093/Neuonc/Nov061.130  0.796
2014 Gholamin S, Fiuji H, Maftouh M, Mirhafez R, Shandiz FH, Avan A. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress. Current Drug Targets. 15: 1302-11. PMID 25382190 DOI: 10.2174/1389450115666141107105456  0.341
2014 Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N, Balansay B, Yu F, Oh S, Woo P, Chen S, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine. 20: 732-40. PMID 24973920 DOI: 10.1038/Nm.3613  0.757
2014 Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher SE, Zeid R, Masoud S, Yu F, Vue N, Gibson WJ, Paolella BR, Mitra SS, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 912-25. PMID 24297863 DOI: 10.1158/1078-0432.Ccr-13-2281  0.749
2014 Mitra SS, Gholamin S, Volkmer J, Feroze A, Liu J, Achrol A, Wang L, Sayles L, Zhang M, Sakamoto K, Monje-Deisseroth M, Cho Y, Sweet-Cordero A, Majeti R, Cheshier S, et al. Abstract PR12: Overcoming immune evasion in pediatric hematologic and solid tumor malignancies: A preclinical study using a humanized anti-CD47 antibody Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr12  0.832
2014 Tang Y, Schubert S, Qi J, Nguyen B, Masoud S, Vue N, Balansay B, Yu F, Atwood SX, Whitson RJ, Ponnuswami A, Chen S, Gholamin S, Pamelyn WJ, Monje-Diesseroth M, et al. Abstract B6: Epigenetic regulation of Hedgehog pathway transcriptional output by BET bromodomain proteins Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B6  0.339
2014 Feroze AH, Lee K, Gholamin S, Wu Z, Weissman I, Lu B, Mitra SS, Cheshier S. Abstract LB-207: mTORC2/Akt signaling is modulated by noncanonical mitochondrial Notch1/PINK1 interaction in myc-amplified medulloblastoma tumorigenesis Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-207  0.809
2014 Kahn SA, Gholamin S, Zhang M, Nitta R, Weissman I, Mitra S, Cheshier S. Abstract 4041: Involvement of Notch1 signaling pathway in medulloblastoma metastasis Cancer Research. 74: 4041-4041. DOI: 10.1158/1538-7445.Am2014-4041  0.817
2014 Feroze A, Lee K, Alrfaei B, Gholamin S, Azad T, Mitra S, Lu B, Cheshier S. CS-07 * mTORC2/Akt SIGNALING IS MODULATED BY NONCANONICAL MITOCHONDRIAL NOTCH-PINK1 INTERACTION IN MEDULLOBLASTOMA (GROUP III) TUMORIGENESIS Neuro-Oncology. 16: v52-v52. DOI: 10.1093/Neuonc/Nou242.7  0.761
2014 Cho Y, Tang Y, Schubert S, Willardson M, Bandopadhayay P, Bergthold G, Nguyen B, Masoud S, Vue N, Balansay B, Gholamin S, Cheshier SH, Atwood SX, Whitson RJ, Lee A, et al. EPIGENETIC TARGETING OF HEDGEHOG PATHWAY TRANSCRIPTIONAL OUTPUT Neuro-Oncology. 16: iii25-iii25. DOI: 10.1093/Neuonc/Nou208.9  0.743
2013 Gholamin S, Feroze AH, Mitra SS, Kahn SA, Cheshier SH. Establishment of Stereotactic Orthotopic Brain Tumor Xenografts in Mice: Technical Report Cureus. DOI: 10.7759/Cureus.150  0.794
2013 Gholamin S, Mitra SS, Richard CE, Achrol A, Kong D, Shin JJ, Monje-Deisseroth M, Cho Y, Weissman I, Cheshier SH. Abstract 5218: Development of Anti-CD47 therapy for pediatric brain tumors. Cancer Research. 73: 5218-5218. DOI: 10.1158/1538-7445.Am2013-5218  0.826
2013 Mitra SS, Gholamin S, Feroze A, Cheshier SH, Weissman IL. Abstract 5007: Delineating human fetal CNS stem cell hierarchy reveals a progenitor cell of origin for human Gliobastoma Multiforme. Cancer Research. 73: 5007-5007. DOI: 10.1158/1538-7445.Am2013-5007  0.823
2013 Adachi K, Sasaki H, Nagahisa S, Yoshida K, Hattori N, Nishiyama Y, Kawase T, Hasegawa M, Abe M, Hirose Y, Alentorn A, Marie Y, Poggioli S, Alshehhi H, Boisselier B, ... ... Gholamin S, et al. OMICS AND PROGNSTIC MARKERS Neuro-Oncology. 15: iii136-iii155. DOI: 10.1093/Neuonc/Not183  0.701
2013 Campian J, Gladstone D, Ambady P, Ye X, King K, Borrello I, Petrik S, Golightly M, Holdhoff M, Grossman S, Bhardwaj R, Chakravadhanula M, Ozols V, Georges J, Carlson E, ... ... Gholamin S, et al. IMMUNOTHERAPY/BIOLOGICAL THERAPIES Neuro-Oncology. 15: iii68-iii74. DOI: 10.1093/Neuonc/Not178  0.738
2013 Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, ... ... Gholamin S, et al. CELL BIOLOGY AND SIGNALING Neuro-Oncology. 15: iii12-iii31. DOI: 10.1093/Neuonc/Not174  0.764
Show low-probability matches.